SI3786160T1 - Piridinski derivati in njihova terapevtska uporaba kot inhibitorjev TRPC6 - Google Patents

Piridinski derivati in njihova terapevtska uporaba kot inhibitorjev TRPC6

Info

Publication number
SI3786160T1
SI3786160T1 SI201830732T SI201830732T SI3786160T1 SI 3786160 T1 SI3786160 T1 SI 3786160T1 SI 201830732 T SI201830732 T SI 201830732T SI 201830732 T SI201830732 T SI 201830732T SI 3786160 T1 SI3786160 T1 SI 3786160T1
Authority
SI
Slovenia
Prior art keywords
therapeutic uses
pyridine derivatives
trpc6
inhibitors
trpc6 inhibitors
Prior art date
Application number
SI201830732T
Other languages
English (en)
Inventor
Thierry Bouyssou
Dirk Gottschling
Niklas Heine
Keenan Lana Louise Smith
Michael D. Lowe
Hossein Razavi
Christopher Ronald Sarko
Simon Surprenant
Hidenori Takahashi
Michael Robert Turner
Xinyuan Wu
Original Assignee
Boehringer Ingelheim International Gmbh
Hydra Biosciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Hydra Biosciences, Llc filed Critical Boehringer Ingelheim International Gmbh
Publication of SI3786160T1 publication Critical patent/SI3786160T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI201830732T 2017-10-27 2018-10-25 Piridinski derivati in njihova terapevtska uporaba kot inhibitorjev TRPC6 SI3786160T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577883P 2017-10-27 2017-10-27
US201862628313P 2018-02-09 2018-02-09
EP20197194.2A EP3786160B1 (en) 2017-10-27 2018-10-25 Pyridine derivatives and therapeutic uses thereof as trpc6 inhibitors

Publications (1)

Publication Number Publication Date
SI3786160T1 true SI3786160T1 (sl) 2022-11-30

Family

ID=64270818

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201830924T SI3700902T1 (sl) 2017-10-27 2018-10-25 Inhibitorji trpc6
SI201830732T SI3786160T1 (sl) 2017-10-27 2018-10-25 Piridinski derivati in njihova terapevtska uporaba kot inhibitorjev TRPC6

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201830924T SI3700902T1 (sl) 2017-10-27 2018-10-25 Inhibitorji trpc6

Country Status (28)

Country Link
US (4) US10889568B2 (sl)
EP (2) EP3786160B1 (sl)
JP (2) JP7217273B6 (sl)
KR (2) KR20200095467A (sl)
CN (1) CN111527078B (sl)
AU (2) AU2018355743B2 (sl)
BR (1) BR112020007818A2 (sl)
CA (1) CA3078769A1 (sl)
CL (2) CL2020001097A1 (sl)
CY (1) CY1126109T1 (sl)
DK (2) DK3786160T3 (sl)
ES (2) ES2946274T3 (sl)
FI (1) FI3700902T3 (sl)
HR (2) HRP20220991T1 (sl)
HU (2) HUE059450T2 (sl)
IL (2) IL274039B (sl)
LT (2) LT3786160T (sl)
MX (1) MX2020004283A (sl)
PE (1) PE20210154A1 (sl)
PH (1) PH12020550503A1 (sl)
PL (2) PL3700902T3 (sl)
PT (2) PT3700902T (sl)
RS (2) RS64271B1 (sl)
SG (2) SG10202011632RA (sl)
SI (2) SI3700902T1 (sl)
TW (2) TWI780246B (sl)
WO (1) WO2019081637A1 (sl)
ZA (1) ZA202002372B (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3700902T1 (sl) * 2017-10-27 2023-10-30 Boehringer Ingelheim International Gmbh Inhibitorji trpc6
US11485740B2 (en) * 2018-02-15 2022-11-01 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
US11370771B2 (en) * 2018-02-16 2022-06-28 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
EP3841095A2 (en) * 2018-08-24 2021-06-30 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
WO2020208002A1 (en) * 2019-04-12 2020-10-15 Boehringer Ingelheim International Gmbh Inhibitors of trpc6
JP2021070688A (ja) * 2019-10-24 2021-05-06 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物
WO2021160625A1 (en) 2020-02-11 2021-08-19 Klinikum Rechts Der Isar Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices
MX2022012923A (es) 2020-04-16 2022-11-16 Boehringer Ingelheim Int Inhibidores de trpc6 para tratar afecciones respiratorias.
AR121846A1 (es) 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
CN113105318B (zh) * 2021-02-23 2022-05-20 中山大学 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用
WO2023062177A1 (en) 2021-10-15 2023-04-20 Boehringer Ingelheim International Gmbh Trpc6 inhibitory compounds for treating sepsis
WO2023106421A1 (ja) * 2021-12-06 2023-06-15 国立大学法人熊本大学 Trpc6の発現を抑制する方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
WO1993000313A2 (en) 1991-06-27 1993-01-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
PL309257A1 (en) 1992-12-02 1995-10-02 Pfizer Pirocatechin doethers as selective inhibitors of ped iv
US6673799B1 (en) 1998-09-22 2004-01-06 Yamanouchi Pharmaceutical Co. Ltd. Cyanophenyl derivative
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
EP1301484A2 (en) 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin receptor ligands
MXPA03011629A (es) * 2001-06-15 2004-07-01 Yamanouchi Pharmaceuticals Co Derivado de fenilpiridincarbonilpiperazina.
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
DE10222291A1 (de) 2002-05-18 2003-11-27 Schlafhorst & Co W Faserbandzuführeinrichtung
CN1150176C (zh) 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
CA2581745A1 (en) 2004-10-13 2006-04-27 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
DE102005044814A1 (de) * 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
PE20070795A1 (es) 2005-10-28 2007-08-24 Lilly Co Eli Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
MX2008008337A (es) 2005-12-21 2008-09-03 Schering Corp Fenoxipiperidinas y sus analogos utiles como antagonistas de histamina h3.
JP5019768B2 (ja) 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
UA100684C2 (uk) 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
JP5082538B2 (ja) 2007-03-28 2012-11-28 Ｄｉｃ株式会社 ピペラジン化合物
WO2010080357A1 (en) 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
US20100234603A1 (en) 2009-03-13 2010-09-16 Xin Linghu Process for Making Substituted Aryl Sulfone Intermediates
US20110039850A1 (en) 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
US8575168B2 (en) 2009-10-09 2013-11-05 Irm Llc Compounds and compositions as modulators of GPR119 activity
US20120232087A1 (en) 2009-11-18 2012-09-13 Silvia Buonamici Methods and compositions for treating solid tumors and other malignancies
WO2011109059A1 (en) 2010-03-01 2011-09-09 Gtx, Inc. Compounds for treatment of cancer
PL2565182T3 (pl) 2010-04-27 2018-03-30 Mitsubishi Tanabe Pharma Corporation Nowa pochodna amidu i jej zastosowanie jako leku
PE20130576A1 (es) 2010-05-13 2013-05-19 Amgen Inc Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
JP5889895B2 (ja) 2010-07-29 2016-03-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｍｐｋ活性化複素環化合物およびその使用方法
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
JP5800786B2 (ja) 2011-10-26 2015-10-28 田辺三菱製薬株式会社 新規アミド誘導体を有効成分として含有する医薬組成物
EP2773199B1 (en) 2011-10-31 2019-04-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN103360343B (zh) 2012-03-30 2017-04-19 凯惠药业(上海)有限公司 一种哌嗪酰胺类化合物的制备方法
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
EP3004089B1 (en) * 2013-05-27 2020-05-06 F.Hoffmann-La Roche Ag New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
EA035499B1 (ru) 2014-01-06 2020-06-25 Ризен Фармасьютикалз Са Новые ингибиторы глутаминазы
WO2015199206A1 (ja) * 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
CN107176927B (zh) 2016-03-12 2020-02-18 福建金乐医药科技有限公司 组蛋白去甲基化酶lsd1抑制剂
ES2947636T3 (es) 2016-03-16 2023-08-14 Kura Oncology Inc Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso
CN110337293A (zh) 2016-06-20 2019-10-15 新泽西鲁特格斯州立大学 治疗性化合物
CN107540636A (zh) 2016-06-29 2018-01-05 成都贝斯凯瑞生物科技有限公司 一种含氮杂环衍生物及其应用
CN106317050B (zh) * 2016-08-24 2018-11-23 烟台大学 一种苯基噻唑衍生物及其制备方法与应用
WO2018159827A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製
WO2018170225A1 (en) 2017-03-15 2018-09-20 Athenex, Inc. Biaryl piperidine amide compounds and methods of use thereof
SI3700902T1 (sl) * 2017-10-27 2023-10-30 Boehringer Ingelheim International Gmbh Inhibitorji trpc6
US11485740B2 (en) * 2018-02-15 2022-11-01 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
US11370771B2 (en) * 2018-02-16 2022-06-28 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6

Also Published As

Publication number Publication date
EP3700902B1 (en) 2023-03-08
US20190169167A1 (en) 2019-06-06
PL3700902T3 (pl) 2023-09-04
DK3786160T3 (da) 2022-08-22
PT3786160T (pt) 2022-08-19
KR20200095467A (ko) 2020-08-10
HRP20220991T1 (hr) 2022-11-11
EP3700902B8 (en) 2023-08-02
HUE062460T2 (hu) 2023-11-28
KR20200125758A (ko) 2020-11-04
DK3700902T3 (en) 2023-05-22
CN111527078B (zh) 2023-06-02
LT3700902T (lt) 2023-06-26
TWI780511B (zh) 2022-10-11
MX2020004283A (es) 2021-10-21
US10889568B2 (en) 2021-01-12
AU2020250185A1 (en) 2020-11-12
PE20210154A1 (es) 2021-01-26
CL2020002562A1 (es) 2021-01-15
US20190169168A1 (en) 2019-06-06
JP7217273B2 (ja) 2023-02-02
PT3700902T (pt) 2023-05-30
RS64271B1 (sr) 2023-07-31
JP7217273B6 (ja) 2024-02-08
EP3786160B1 (en) 2022-07-13
TWI780246B (zh) 2022-10-11
WO2019081637A1 (en) 2019-05-02
IL277493A (en) 2020-11-30
PL3786160T3 (pl) 2022-10-24
US20210163449A1 (en) 2021-06-03
CY1126109T1 (el) 2023-11-15
RS63535B1 (sr) 2022-09-30
SG11202003367TA (en) 2020-05-28
JP6979502B2 (ja) 2021-12-15
AU2018355743B2 (en) 2022-04-14
ZA202002372B (en) 2023-10-25
USRE49699E1 (en) 2023-10-17
TW201930294A (zh) 2019-08-01
JP2021500390A (ja) 2021-01-07
IL274039B (en) 2021-08-31
CA3078769A1 (en) 2019-05-02
CN111527078A (zh) 2020-08-11
TW202120494A (zh) 2021-06-01
PH12020550503A1 (en) 2021-03-22
IL277493B (en) 2022-02-01
FI3700902T3 (fi) 2023-05-25
ES2946274T3 (es) 2023-07-14
BR112020007818A2 (pt) 2020-10-20
SI3700902T1 (sl) 2023-10-30
US10800757B2 (en) 2020-10-13
ES2924933T3 (es) 2022-10-11
EP3700902A1 (en) 2020-09-02
JP2021008503A (ja) 2021-01-28
AU2018355743A1 (en) 2020-05-14
SG10202011632RA (en) 2021-01-28
LT3786160T (lt) 2022-09-26
HRP20230502T1 (hr) 2023-09-15
AU2020250185B2 (en) 2022-04-14
IL274039A (en) 2020-06-30
CL2020001097A1 (es) 2020-08-28
EP3786160A1 (en) 2021-03-03
HUE059450T2 (hu) 2022-11-28

Similar Documents

Publication Publication Date Title
PT3786160T (pt) Derivados de piridina e suas utilizações terapêuticas como inibidores de trpc6
IL253712B (en) Mysterlein derivatives for coupling and healing
PL3287443T3 (pl) 6-członowa pochodna heterocykliczna i kompozycja farmaceutyczna ją zawierająca
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
IL258978B (en) The use of pyrimidine and pyridine derivatives in the treatment of multiple sclerosis
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
HK1250161B (zh) 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途
PL3487851T3 (pl) Pochodne aminopirydyny i ich zastosowanie jako selektywnych inhibitorów alk-2
HK1250028A1 (zh) 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途
IL261645A (en) History of dioxo-hexahydroisoindolyl and their use as cyclophilin inhibitors
IL274722A (en) History of pyridinones and their use as selective inhibitors of ALK-2
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
EP3253734A4 (en) Glucosylceramide synthase inhibitors and therapeutic methods using the same
ZA202000959B (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
IL261644A (en) Oxalyl derivatives and their use as cyclophilin inhibitors
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors